Yinin Hu is an Oncology physician affiliated with University of Maryland, Baltimore. OpenAlex indexes 115 publications with 2,138 citations (h-index 22).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
419 W Redwood St Ste 300
Baltimore, MD 212017003
Telephone
667-214-1718Provider last certified this registry record 1 Oct 2020.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Lilly USA, LLCProgram year20231 payment
- Rhythm Pharmaceuticals, Inc.Program year20231 payment
- Alexion Pharmaceuticals, Inc.Program year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Hormonal (systemic)
72.7%l-Thyroxine72.7%Levothyroxine Sodium100%Part D≥18 patientsNervous system
27.3%Opioid Agonist27.3%Oxycodone Hcl100%Part D≥12 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2024–2026 per NIH RePORTER. The latest:
- Preference-Based Treatment Valuation in Low-Risk Thyroid Cancer
University of Maryland Baltimore
FY2026$284,358K08CA293167 - Preference-Based Treatment Valuation in Low-Risk Thyroid Cancer
University of Maryland Baltimore
FY2025$279,606K08CA293167 - Preference-Based Treatment Valuation in Low-Risk Thyroid Cancer
University of Maryland Baltimore
FY2024$279,039K08CA293167
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Differential Electronic Survey Response: Does Survey Fatigue Affect Everyone Equally?
Journal of Surgical Research
2023 - Monitoring performance in laparoscopic gastric bypass surgery using risk-adjusted cumulative sum at 2 high-volume centers
Surgery for Obesity and Related Diseases
2023 - Low-Risk Papillary Thyroid Cancer: Treatment De-Escalation and Cost Implications
Journal of Surgical Research
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Steven Kittner
University of Maryland, Baltimore
Edward Sausville, MD
University of Maryland, Baltimore
Aloke Finn, MD
University of Maryland, Baltimore
Christopher Plowe, MD
University of Maryland, Baltimore
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”